NTHI - NeOnc Technologies Holdings, Inc. Common Stock

NTHI - NeOnc Technologies Holdings, Inc. Common Stock

https://www.neonc.com

Recent News

Powered by Alpha Vantage

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

GlobeNewswire • 5 days, 2 hours ago • score: -0.02

CALABASAS, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- NeOnc Technologies Holdings, Inc. ( NASDAQ: NTHI ) ( "NeOnc" or the "Company" ) , a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system ( CNS ) cancers, today announced that the U.S.

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer - NeOnc Technologies Hldgs ( NASDAQ:NTHI )

Benzinga • 5 days, 2 hours ago • score: 0.01

CALABASAS, Calif., Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- NeOnc Technologies Holdings, Inc. NTHI ( "NeOnc" or the "Company" ) , a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system ( CNS ) cancers, today announced that the U.S.

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

GlobeNewswire • 3 weeks, 6 days ago • score: 0.22

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- NeOnc Technologies Holdings, Inc. ( NASDAQ: NTHI ) , a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system ( CNS ) cancers, today announced financial results ...

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

GlobeNewswire • 1 month ago • score: 0.26

Quazar Chairman and Executive Team with NeOnc's Executive's and Directors at Quazar's Headquarters in Dubai.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$25.00

52W Low

$3.20

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

1046.10

P/S (TTM) (<3 favorable)

1134.61

P/B (<3 favorable)

N/A

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

53.00%

Institutions (25–75% balanced)

0.31%

Shares Outstanding

19,026,800

Float

8,005,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-03-31 (Overview)

Revenue (TTM)

79,990

Gross Profit (TTM)

79,990

EPS (TTM)

-2.47

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-939.66%

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.07

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—